The cover for issue 9 of Oncotarget features Figure 6, ‘BCL6 knock-out in a DLBCL xenograft induces tumor stasis,’ by Schlager, et al.
Credit: Manfred Koegl — [email protected]
The cover for issue 9 of Oncotarget features Figure 6, “BCL6 knock-out in a DLBCL xenograft induces tumor stasis,” by Schlager, et al.
Read more: An oncogenic role of BCL6 in the initiation of DLBCL has been shown as the constitutive expression of BCL6 in mice recapitulates the pathogenesis of human DLBCL. Conditional BCL6 deletion in established DLBCL tumors in vivo induced a significant tumor growth inhibition with initial tumor stasis followed by slow tumor growth kinetics.
Dr. Manfred Koegl from Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria said, “DLBCL is an aggressive and genetically diverse B-cell neoplasm in adults resulting in a biologically and clinically heterogeneous disease.”
Such genetic alterations include translocations that fuse its coding sequence to heterologous promoters, point mutations in BCL6 promoter negative regulatory elements or mutations that affect BCL6 transcription, acetylation-mediated BCL6 inactivation or BCL6 degradation.
Constitutive BCL6 expression within GC B-cells leads to the development of DLBCL in mice that mimics that observed in patients suggesting that BCL6 is sufficient to initiate cancer.
A variety of BCL6 inhibitors have been previously reported, several of which have demonstrated that the BTB domain of BCL6 is amenable to targeting with peptide and small molecule inhibitors as well as PROTACs.
Importantly, we found that the anti-proliferative activity of BCL6 degraders such as BI-3802 on tissue culture cells is generally higher than that of BCL6 inhibitors despite their equipotent BCL6 binding affinities.
Addressing this question, we report on the establishment of an inducible BCL6 knock-out DLBCL model, which allows studying the phenotype of BCL6 loss in DLBCL xenografts in vivo.
The Koegl research team concluded in their Oncotarget Research Paper, “our findings have important implications for understanding the impact of BCL6-targeted therapies in DLBCL. According to our studies, it is reasonable to predict that the treatment of DLBCL with BCL6 degraders results in significant tumor growth inhibition and at least tumor stasis. The observed magnitude of effects of BCL6 blockade in monotherapy might provide a rationale for therapeutic combinations with other targeted and/or chemotherapeutic agents. Our CRISPR/Cas9 BCL6 knock-out model represents a valuable pre-clinical tool to evaluate such combination approaches.”
###
Sign up for free Altmetric alerts about this article
DOI – https:/
Full text – http://www.
Correspondence to – Manfred Koegl – [email protected]
Keywords – BCL6, DLBCL, lymphoma, inducible CRISPR/Cas9, in vivo xenograft
About Oncotarget
Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit http://www.
SoundCloud – https:/
Facebook – https:/
Twitter – https:/
LinkedIn – https:/
Pinterest – https:/
Reddit – https:/
Oncotarget is published by Impact Journals, LLC please visit http://www.
Media Contact
[email protected]
18009220957×105
Media Contact
Ryan James Jessup
[email protected]
202-638-9720
Original Source
http://www.
Related Journal Article
http://dx.
